ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong · Delayed Price · Currency is HKD 3.000
+0.080 (2.74%)
Jul 31, 2026, 4:08 PM HKT
HKG:1541 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 679.56 | 477.6 | 306.98 | 635.21 | 668.33 |
Short-Term Investments | 40 | - | 42.5 | - | - |
Trading Asset Securities | 296.46 | 274.52 | 259.09 | - | - |
Cash & Short-Term Investments | 1,016 | 752.12 | 608.56 | 635.21 | 668.33 |
Cash Growth | 35.09% | 23.59% | -4.20% | -4.96% | - |
Accounts Receivable | 0 | 0.02 | 0.04 | 0.07 | 0.03 |
Other Receivables | 14.15 | 0.17 | 1.04 | 0.96 | 0.02 |
Receivables | 14.15 | 0.18 | 1.08 | 1.02 | 0.06 |
Inventory | 25.56 | 24.54 | 76.77 | 9.04 | 19.42 |
Other Current Assets | 0.97 | 91.09 | 0.29 | 6.59 | 16.3 |
Total Current Assets | 1,057 | 867.94 | 686.7 | 651.87 | 704.1 |
Property, Plant & Equipment | 33.53 | 47.71 | 149.39 | 163.89 | 154.12 |
Other Long-Term Assets | 8.17 | 6.35 | 38.5 | 24.22 | 34.62 |
Total Assets | 1,098 | 922 | 874.59 | 839.98 | 892.84 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 13.68 | 43.24 | 10.8 | 1.26 | 1.76 |
Accrued Expenses | 37.03 | 28.59 | 30.86 | 28.91 | 24.17 |
Short-Term Debt | - | - | 59.98 | - | - |
Current Portion of Long-Term Debt | 188.47 | 100.89 | - | - | - |
Current Portion of Leases | 6.86 | 6.42 | 4.4 | 5.6 | 5.1 |
Current Income Taxes Payable | 1.3 | 1.11 | 0.77 | 0.61 | 2.96 |
Current Unearned Revenue | 25.25 | 32.9 | - | - | - |
Other Current Liabilities | 2.98 | 1.49 | 9.11 | 15.36 | 2,444 |
Total Current Liabilities | 275.57 | 214.64 | 115.91 | 51.74 | 2,478 |
Long-Term Debt | 25.5 | 14.5 | - | - | - |
Long-Term Leases | 7.2 | 14.55 | 10.4 | 9.02 | 13.44 |
Total Liabilities | 308.27 | 243.69 | 126.3 | 60.76 | 2,491 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 431.51 | 407.31 | 374.16 | 356.09 | 6.91 |
Additional Paid-In Capital | 1,384 | 1,093 | 913.46 | 654.47 | - |
Retained Earnings | -1,245 | -1,026 | -710.35 | -330.89 | -1,638 |
Comprehensive Income & Other | 221.06 | 205.21 | 171.01 | 99.54 | 32.24 |
Total Common Equity | 791.44 | 678.9 | 748.29 | 779.22 | -1,598 |
Minority Interest | -1.3 | -0.6 | - | - | - |
Shareholders' Equity | 790.13 | 678.31 | 748.29 | 779.22 | -1,598 |
Total Liabilities & Equity | 1,098 | 922 | 874.59 | 839.98 | 892.84 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 228.03 | 136.36 | 74.77 | 14.62 | 18.54 |
Net Cash (Debt) | 788 | 615.76 | 533.79 | 620.59 | 649.79 |
Net Cash Growth | 27.97% | 15.36% | -13.99% | -4.49% | - |
Net Cash Per Share | 1.91 | 1.63 | 1.48 | 1.87 | 7.54 |
Filing Date Shares Outstanding | 431.51 | 407.31 | 374.16 | 356.09 | 86.18 |
Total Common Shares Outstanding | 431.51 | 407.31 | 374.16 | 356.09 | 86.18 |
Working Capital | 781.14 | 653.3 | 570.79 | 600.13 | -1,774 |
Book Value Per Share | 1.83 | 1.67 | 2.00 | 2.19 | -18.55 |
Tangible Book Value | 791.44 | 678.9 | 748.29 | 779.22 | -1,598 |
Tangible Book Value Per Share | 1.83 | 1.67 | 2.00 | 2.19 | -18.55 |
Machinery | 53.82 | 52.89 | 51.44 | 49.93 | 40.87 |
Construction In Progress | - | 27.4 | 22.69 | 22.46 | 3.22 |
Leasehold Improvements | 22.49 | 22.49 | 22.49 | 22.49 | 21.07 |